Friday, March 8, 2019

Trovagene Inc. (TROV)

Focus on upcoming catalyst, 2018 earnings review and early 2019 developments.

TrovaGene Inc is a US-based life science company which focuses on the development and commercialization of a proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research and medical testing across a variety of clinical disciplines, including oncology and virology. 

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.  

• Progressing clinical programs. The company continues to focus on
  advancement of its clinical programs. We have seen two clinical trials readouts
  up to date 1) from Phase 1b/2 acute myeloid leukemia (AML) study-
  demonstrating favorable clinical benefit (80% disease control rate) among 12
  acute myeloid leukemia (AML) patients and 2) from Phase 1/2 metastatic
  castration resistant prostate cancer (mCRPC) program- leading to dosing
  adjustments to extend drug exposure and clinical benefit in mCRPC patients.
• Upcoming catalysts.  We are expecting to see a few key value generating
  events 1) further data readouts from Phase 1b/2 acute myeloid leukemia
  (AML) program at American Association for Cancer Research (AACR) annual
  meeting, 2) data readout f…
  

  
  
  
  
  

  Get full report on Channelchek desktop.

*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.